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A B S T R A C T
Background: Although detection of children at high risk of developing type 1 diabetes and diagnosis of early
stages is possible, up to now there exists no approved therapy to delay or prevent type 1 diabetes. Thus it is vital
to develop evidence-based interventions. For this a sufficient number of trial participants is crucial but difficult
to obtain especially in asymptomatic children.
Aim: Identifying family characteristics that lead to or impede trial participation and analyze reasons stated by
families for non-participation.
Methods: Participants for the Fr1da Insulin Intervention study are recruited from the Fr1da study, a population
based screening for early stage type 1 diabetes in Bavaria. Families with eligible children were invited to enroll.
We analyzed sex and age of the child, distance of the family to the study center in Munich and the existence of a
first degree family member with type 1 as possible influential factors for study participation. We also analyzed
reasons stated by families who declined study participation in a phone interview.
Results: Of 146 eligible children 77 (53%) were enrolled into the trial. None of the tested family characteristics
differed significantly between the enrolling and the families not participating, but in general enrolling families
lived closer to the study site than families not participating. This is also reflected in the reasons given by non-
participating families. The most frequent reason stated were time restrictions. The second most frequent reason
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was the venous blood draw.
Conclusion: The factors for non-participation identified in this project need be taken into account for the design
of future trials in young children to ensure proper recruitment and thus to generate valid results for medical
treatment of children. More research on the reason of participation and non-participation in clinical trials is
needed.
1. Introduction
Recruitment of research participants into pediatric clinical trials is a
major issue that investigators and sponsors have to tackle. The pool of
eligible children is often small, and the threshold for gaining consent is
often higher and more complex because parents have to make decisions
about trial participation on behalf of their child.
Nevertheless, recruitment of patients into clinical trials is crucial for
reaching target sample size and being able to test the trial hypotheses
with adequate power. Only with a sufficient number of participants it is
possible to provide evidence-based results for the development of
therapies and medical strategies for several diseases like type 1 diabetes
in children.
While there is quite some insight into recruitment practices and
problems in adults [1–4], especially for severe diseases like cancer
[5–7], evidence on successful techniques of increasing recruitment
numbers is still sparse [8,9].
This is even more true for pediatric trials recruiting infants.
Recruitment strategies [10] and participant characteristics that predict
recruitment are rarely reported [11]. For preventive trials in asymp-
tomatic children the problem of slow recruitment seems to be even
more evident [12] but not much information is available on this topic.
In the Fr1da Insulin Intervention study children with early type 1
diabetes receive oral insulin or placebo for 12 months as a secondary
prevention in order to test immune efficacy of oral insulin up to a dose
of 67.5 mg. Early type 1 diabetes is characterized by multiple islet au-
toantibodies. The dose of oral insulin was defined in a preceding pilot
study (Pre-Point) that demonstrated that this dose resulted in an im-
mune response with signs of T cell regulation [13].
Almost all children eligible for the trial will develop symptomatic
T1D in the near future [14]. While T1D is well treatable, it still comes
with significant restrictions due to disease-specific problems for chil-
dren [15] and their parents [16]. Despite that recruitment into the trial
was slower than expected. Here we cover the difficulties in recruitment
of children and their parents for participation in the study.
2. Methods
The first step of the project is a population based screening for early
stage type 1 diabetes - the Fr1da study (ethics no.: 70/14) [17]. In-
clusion criteria were:
1. The child is between 2 and 5 years old
2. The child is living in Bavaria, Germany.
The screening is offered by primary care and has been established in
January 2015. It is still ongoing and aiming to include 100,000 chil-
dren. The concept of the Fr1da study was published by Raab et al. [18].
In a second step all children participating in the screening and di-
agnosed with antibodies to glutamic acid decarboxylase (GAD65), to
insulin (IAA), autoantibodies to IA-2 (IA2A), or autoantibodies to zink
transporter 8 (ZnT8A) are asked to participate in the Fr1da Insulin
Intervention trial. Parents were contacted to schedule an appointment
for an initial visit.
The Fr1da Insulin Intervention study is a randomized, placebo-
controlled, double-blind, mono-center secondary intervention study of
high-dose oral insulin to delay or prevent clinical symptomatic type 1
diabetes (clinicaltrials.gov NCT02620072).
A child is eligible for the Fr1da Insulin Intervention trial if it:
1. is two to 12 years old
2. has at least two confirmed positive islet autoantibodies out of
GADA, IAA, IA2A, or ZnT8A and time between screening sample
collection and randomization did not exceed 90 days.
3. has a normal glucose tolerance after an oral glucose tolerance test.
Normal glucose tolerance is defined as fasting glucose< 110mg/dl,
and a glucose level 2 h after ingestion of oral glucose< 140mg/dl,
and intermediate glucose levels at 30min and 60min and 90min
after ingestion of oral glucose< 200mg/dl.
Included children are randomized to the insulin or placebo group in
a 1:1 ratio. The allocated study capsules are administered for 12 months
as powder spotted on food. Children who completed the intervention
period and who have not developed type 1 diabetes will be continued to
be monitored for at least one year and a maximum of 7 years. Study
related burdens are daily administration of insulin powder in food over
12 months and five study visits during the one-year intervention period
at the study site in Munich, taking approximately 2.5 h including a
physical examination, a saliva sample and a venous blood draw with
five sampling times. Additionally, an OGTT is performed and stool is
collected every six months. After the intervention period families are
asked to visit the study site every six months. During each visit an OGTT
will be performed. During the whole observation period families are
asked to document adverse events and additional medications.
This manuscript consists of two main analyses:
1. Parents of eligible children who did not agree to participate in the
trial were called and asked for reasons for their non-participation.
The reasons given by the parents were categorized. Percentages,
medians and ranges were calculated according to the data type.
2. We analyzed sex and age of the child, distance of the family to the
study center in Munich and the existence of a first degree family
member with type 1 diabetes of all eligible children. To identify if
those factors were influencing the participation in the trial we cal-
culated a logistic regression model. From this model we calculated
Odds Ratios and the respective 95% confidence limits and the p
Table 1
Baseline characteristics of eligible patients and Odds Ratios and p values from the logistic regression model.
All Participating Not participating Odds ratio (95% CI) P value
N 146 77 69 – –
Median Age in years (Min-Max) 4 (2–10) 4 (2–10) 4 (2–10) 1.09 (0.88–1.35) 0.4511
Male sex, n (%) 84 (58) 43 (56) 41 (59) 0.78 (0.39–1.53) 0.4633
First degree relative with type 1 diabetes, n (%) 21 (14) 12 (16) 9 (13) 0.98 (0.36–2.66) 0.9685
Median distance to study center in km (Min-Max) 88 (0–270) 68 (0–270) 88 (0–270) 1.00 (0.99–1) 0.0699
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values of the Wald test.
3. Results
Overall, by January 2018 72,192 children were screened in the
context of the Fr1da-study and 146 Fr1da children who were eligible
according to the inclusion criteria were invited to participate in the
Fr1da Insulin Intervention trial. Of those 77 (53%) were eventually
enrolled in the study. Baseline characteristics are described in Table 1.
Neither the age of the child nor sex, distance to the study center or a
first degree relative with type 1 diabetes had a significant influence on
the decision to participate in the study.
The parents who declined trial participation for their children were
asked for the main reason on the phone. Of 69 families who did not
participate in the study 61 responded to the call (Fig. 1). Table 2
summarizes the reasons given by the parents for not participating in the
study.
Most parents stated time issues as their main reason for refusal
(36%). Regarding this, families state long travelling distance especially
if they have more children. Consequentially, only 19% of the families
from Munich state time as the main reason for non-participation while
42% of families do so who need to travel longer. The second most
frequent reason for refusal was the venous blood draw (30%). 11% of
parents did not specify their decision. 8% of the parents were still un-
decided whether they should agree to participate in the study. These
parents will be contacted again. 7% of the parents were not convinced
of the concept of the study and stated no need to participate in an in-
tervention trial to prevent type 1 diabetes. The same number defined
the possibility to receive placebo as main reason for refusal. Just one
family did not want to be contacted by the study team.
4. Discussion
Participants of randomized clinical trials (RCTs), including those
assigned to placebo, have outcomes similar to or better than those of
eligible non-participants. In the case of type 1 diabetes, participants
may have lower complication rates at disease onset with a significant
reduction in the frequency of diabetic ketoacidosis, a better long term
metabolic control, and a reduction in hospitalization rates compared to
children outside of RCTs [19].
Continuous monitoring of the blood glucose as part of the Fr1da
Insulin Intervention study prevents undiscovered changes in glucose
metabolism. Medical attendance and training by the study team pro-
vides the families with information about the disease and facilitates
coping with type 1 diabetes, especially for families with no experience
concerning the disease. Taken together participation in the Fr1da
Insulin Intervention study might result in an improved medical care
[20–22]. Also, the intervention with high-dose oral insulin was shown
to be safe in the Pre-POINT study [12], in the Pre-POINT Early study
(clinicaltrials.gov NCT02547519) and in the TrialNet TN20 trial
(clinicaltrials.gov NCT02580877) using an even higher dose (ADA oral
presentation 2017). Thus it seems surprising that almost half of the
parents of eligible children who were informed of the study did not
enroll their children.
Neither age nor sex of the child nor a relative with type 1 diabetes
influenced parental decision on trial participation. Also the use of
placebo in the control group was not a major reason for non-partici-
pation as it was reported in other research [23]. The two main reasons
for non-participation were time restrictions and the venous blood draw.
Time restriction is also mirrored in the distance to study center. Fa-
milies enrolling in the trial lived closer to the study site than families
refusing to enroll. Especially families with more than one child were
reluctant to enroll if they needed to travel longer and study participa-
tion would use up a lot of time, also because older children miss school
and have to catch up missed material.
Non-enrolling families stating as their main reason the venous
blood-draw often reported either negative experiences with previous
venous blood draws or a general reluctance regarding such interven-
tions. As soon as the induction of immune efficacy and immune reg-
ulation using oral insulin at a dose of 67.5mg has been demonstrated in
this secondary prevention study, future studies may be able to replace
venous blood draws by a capillary blood test thereby facilitating easier
recruitment to this type of studies.
A limitation of our work is that we unfortunately do not have more
information on families to explore reasons for non-participation in more
detail such as socioeconomic status, parental education or length of the
initial information visit that were shown to be relevant for participation
in other studies [11,24].
A French review on the topic of recruitment in pediatric clinical
trials reports much lower rates of non-participation (median refusal rate
12.5%) [24] than we saw in the Fr1da insulin intervention trial (47%).
This might in part be due to the structure of the study but could also
reflect some pre-selection occurring in other trials. Usually there are
two barriers to trial participation: which eligible families are ap-
proached by the doctor and do these families agree to enroll. In our
scenario with a population based screening without any preselection as
a prerequisite to trial inclusion we see that efforts to inform families
better about the benefits and lower the burden of clinical trials could
result in much higher rates of study participation.
5. Conclusions
This project shows the lack of information on the reasons why fa-
milies decline or agree to enroll their children into clinical trials and
points out why it is important to identify factors that impede trial
participation in children. The factors identified in this study were
mainly time restrictions and the venous blood draw. These factors may
be taken into account for future designs of trials in pediatric population,
or be taken up in awareness and education programs to better inform
Fig. 1. Flowchart of the transfer of children from the Fr1da screening to the
Fr1da Insulin Intervention Trial.
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families of the necessity and impact of certain trial elements. To max-
imize the benefit for participating children and the scientific commu-
nity the benefits for parents and their children have to be highlighted:
currently there is no known treatment to prevent or delay type 1 dia-
betes in children or adults but study participants will have the oppor-
tunity to access a promising treatment to delay or even avoid clinical
symptomatic diabetes [25].
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